Paper40148484
Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma.
Canelo-Vilaseca M and 6 others. Bone Marrow Transplant, 2025. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma. Papers, record 40148484. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40148484
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptors, Chimeric Antigen | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Lymphocyte Depletion | Major topic |
| Lymphoma | Major topic |
| Humans | |
| Cyclophosphamide | |
| Hematopoietic Stem Cell Transplantation |
Source PubMed
References88
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16203864 | Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. | J Exp Med | 2005 | https://conductscience.org/library/papers/16203864 | PubMed |
| 2 | 30518502 | Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/30518502 | PubMed |
| 3 | 35690221 | Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. | Ann Oncol | 2022 | https://conductscience.org/library/papers/35690221 | PubMed |
| 4 | 36122385 | Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. | Blood | 2022 | https://conductscience.org/library/papers/36122385 | PubMed |
| 5 | 3305705 | The stable and permanent expansion of functional T lymphocytes in athymic nude rats after a single injection of mature T cells. | J Immunol | 1987 | https://conductscience.org/library/papers/3305705 | PubMed |
| 6 | 34923107 | Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). | Ann Oncol | 2022 | https://conductscience.org/library/papers/34923107 | PubMed |
| 7 | 35940526 | Perspective: An International Fludarabine Shortage: Supply Chain Issues Impacting Transplantation and Immune Effector Cell Therapy Delivery. | Transplant Cell Ther | 2022 | https://conductscience.org/library/papers/35940526 | PubMed |
| 8 | 29385370 | Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29385370 | PubMed |
| 9 | 28774879 | Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. | Blood | 2017 | https://conductscience.org/library/papers/28774879 | PubMed |
| 10 | 36059523 | Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients. | Front Immunol | 2022 | https://conductscience.org/library/papers/36059523 | PubMed |
| 11 | 30919158 | Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma. | Curr Oncol Rep | 2019 | https://conductscience.org/library/papers/30919158 | PubMed |
| 12 | 34799485 | Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation. | Am J Surg Pathol | 2022 | https://conductscience.org/library/papers/34799485 | PubMed |
| 13 | 35156195 | In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma. | Clin Pharmacol Ther | 2022 | https://conductscience.org/library/papers/35156195 | PubMed |
| 14 | 12242449 | Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. | Science | 2002 | https://conductscience.org/library/papers/12242449 | PubMed |
| 15 | 24914142 | Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. | Blood | 2014 | https://conductscience.org/library/papers/24914142 | PubMed |
| 16 | 38187393 | Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. | Front Immunol | 2023 | https://conductscience.org/library/papers/38187393 | PubMed |
| 17 | 30809033 | Early and late hematologic toxicity following CD19 CAR-T cells. | Bone Marrow Transplant | 2019 | https://conductscience.org/library/papers/30809033 | PubMed |
| 18 | 32888407 | Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. | Lancet | 2020 | https://conductscience.org/library/papers/32888407 | PubMed |
| 19 | 28408462 | Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. | Blood | 2017 | https://conductscience.org/library/papers/28408462 | PubMed |
| 20 | 37668287 | Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma. | Am J Hematol | 2023 | https://conductscience.org/library/papers/37668287 | PubMed |
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42969556 | Bendamustine induces peripheral lymphodepletion in dogs with relapsed lymphoma. | J Vet Intern Med | 2026 | https://conductscience.org/library/papers/42969556 | PubMed |
| 42921052 | When, Where, and How Much: Toward Smarter Design and Delivery of CAR T‑Cell Therapy. | ACS Bio Med Chem Au | 2026 | https://conductscience.org/library/papers/42921052 | PubMed |
| 42482101 | TCM-derived immunometabolic modulators as systems adjuvants for CAR-T therapy in solid tumors: evidence hierarchy and translational roadmap. | J Transl Med | 2026 | https://conductscience.org/library/papers/42482101 | PubMed |
| 42432811 | iPSC-Derived iNK Progenitors Engraft and Generate NK Cells in Unconditioned and Autologous Immune Humanized Mice. | Cell Prolif | 2026 | https://conductscience.org/library/papers/42432811 | PubMed |
| 42411850 | Optimizing Clinical Study Designs for CAR-T Cell Therapy: Development of an Efficient Sampling Strategy Through Optimal Experimental Design. | CPT Pharmacometrics Syst Pharmacol | 2026 | https://conductscience.org/library/papers/42411850 | PubMed |
| 42355450 | B Cells and B Cell Depletion in Autoimmunity and Atherosclerosis. | Life (Basel) | 2026 | https://conductscience.org/library/papers/42355450 | PubMed |
| 42245651 | Designing universal T cell therapies: strategies to evade natural killer cells. | Front Immunol | 2026 | https://conductscience.org/library/papers/42245651 | PubMed |
| 42158862 | Cytokine release syndrome after allogeneic hematopoietic stem cell transplantation using posttransplant cyclophosphamide: current understanding and management. | Front Immunol | 2026 | https://conductscience.org/library/papers/42158862 | PubMed |
| 41978748 | Combining Small-Molecular Compounds With CAR T-Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy. | Cancer Innov | 2026 | https://conductscience.org/library/papers/41978748 | PubMed |
| 41893014 | From Immunobiology to Clinical Application: Tumor-Infiltrating Lymphocytes in Melanoma. | J Pers Med | 2026 | https://conductscience.org/library/papers/41893014 | PubMed |
| 41817579 | The Conflicting Role of Myeloid Cells in CAR T-Cell Therapy. | Cancer Res | 2026 | https://conductscience.org/library/papers/41817579 | PubMed |
| 41799502 | Put the CAR-T before the HRS: Advances in Anti-CD30 Immunotherapy Targeting Hodgkin/Reed-Sternberg Cells in Classical Hodgkin Lymphoma. | Oncol Res | 2026 | https://conductscience.org/library/papers/41799502 | PubMed |
| 41793185 | Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41793185 | PubMed |
| 41792262 | Progress in the development of cytokine armoured CAR T cells. | Nat Rev Immunol | 2026 | https://conductscience.org/library/papers/41792262 | PubMed |
| 41659486 | Rapid receptor internalization potentiates CD7-targeted lipid nanoparticles for efficient mRNA delivery to T cells and in vivo CAR T-cell engineering. | bioRxiv | 2026 | https://conductscience.org/library/papers/41659486 | PubMed |
| 41471106 | Towards Personalized Lymphodepletion: A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell Therapy. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/41471106 | PubMed |
| 41280924 | Precision medicine with car cells in acute myeloid leukemia: where are we? | Front Immunol | 2025 | https://conductscience.org/library/papers/41280924 | PubMed |
| 41279526 | Precision targeting of autoreactive B cells in systemic lupus erythematosus using anti-9G4 idiotope synthetic immune receptor T cells. | bioRxiv | 2025 | https://conductscience.org/library/papers/41279526 | PubMed |
| 41250215 | In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies. | Exp Hematol Oncol | 2025 | https://conductscience.org/library/papers/41250215 | PubMed |
| 41052891 | Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspective. | RMD Open | 2025 | https://conductscience.org/library/papers/41052891 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40148484
GET https://conductscience.org/api/papers/v1/40148484/references?page=2